Clinical Compliance & QoE Defense Architecture

What QoE Will Find

Before an institutional buyer makes an offer, their Quality of Earnings team will conduct a forensic review of the practice's financials, operations, and clinical data. Every vulnerability they find reduces the offer — either through direct EBITDA adjustment, reserve requirements, or multiple compression.

This is not a financial audit in the CPA sense. A QoE review is a deal-specific, adversarial analysis designed to identify every dollar of risk in the seller's reported financials. The QoE team works for the buyer. Their incentive is to find problems — because every problem they identify reduces the price the buyer pays. They have access to national payer databases, clinical benchmarking tools, and algorithmic auditing platforms that most dental practice owners have never encountered.

PDA's compliance audit identifies these vulnerabilities before the buyer does. The strategic advantage is asymmetric: a vulnerability identified and remediated 18 months before the transaction costs a fraction of the same vulnerability discovered during QoE. In QoE, discoveries become negotiation weapons. Before QoE, they're remediation opportunities.

Owner Dependency Assessment

PDA reviews every process in the practice against SOP documentation and measures adherence rates. Processes that exist only in the owner's head are key-person dependencies. Each dependency reduces the practice's owner-independence score — the primary factor in whether a buyer applies a premium or discount multiple.

The assessment covers three domains:

Clinical processes

Treatment planning protocols, case presentation methodology, clinical documentation standards, diagnostic criteria for common conditions, referral decision trees. If the owner is the only person who knows how treatment decisions are made, the clinical process dies when the owner leaves. Buyers recognize this as revenue concentration risk.

Financial processes

Billing protocols, claims submission workflows, denial management procedures, patient collection scripts, fee schedule management, financial reporting cadence. If the bookkeeper or office manager handles these without documented protocols, the system is fragile and owner-dependent by proxy.

Operational processes

Hiring and onboarding procedures, staff training protocols, equipment maintenance schedules, vendor management, compliance monitoring, marketing campaign management. Every process that relies on a specific person's institutional knowledge rather than a documented, trainable system is a dependency that adds risk to the buyer's model.

The remediation path is straightforward but time-intensive: document every process as a written SOP, train multiple staff members on execution, measure adherence rates over 6+ months, and demonstrate that the practice operates without the owner's daily involvement in routine decisions. This is one of the primary reasons PDA recommends an 18-24 month exit runway — the operational transition from owner-dependent to system-dependent takes time.

Auditable Revenue — The Cotiviti Example

PDA reviews clinical procedures against insurance benchmarks — not ADA clinical standards, because insurance auditors don't use ADA standards, and neither do QoE teams. Institutional buyers deploy algorithmic auditing software like Cotiviti to flag ratio anomalies before the LOI is even signed.

The Trojan Horse: Core Buildup-to-Crown Ratio

The core buildup-to-crown ratio measures how frequently a practice places a core buildup (D2950/D2954) relative to crown procedures (D2740-D2799). The clinical rationale for a buildup is that missing tooth structure exceeds 50% and requires structural reinforcement before crown placement.

Cotiviti benchmarks this ratio at approximately 40% — meaning buildups should appear on roughly 40% of crown procedures. This is more conservative than ADA clinical guidelines because Cotiviti's threshold reflects insurance payer expectations, not clinical textbook recommendations.

A practice showing a 76.9% buildup-to-crown ratio is nearly double the institutional benchmark. Every excess buildup — every instance above the 40% threshold — represents non-defensible production that is at risk of:

• Retroactive claim denial: Insurance carriers can audit historical claims and deny reimbursement for buildups that lack clinical documentation of >50% missing tooth structure
• Audit-triggered clawback: Cotiviti findings can trigger a formal insurance audit that results in recoupment demands for previously paid claims
• QoE production write-down: The buyer's QoE team will identify the excess buildup production as non-defensible revenue and deduct it from pro-forma EBITDA

Your average $5M founder has never heard of Cotiviti. Their CPA hasn't either. Their dental-specific attorney may have heard of it in the abstract but has never seen it deployed against a client. That's exactly why it appears in a QoE report as a surprise — and surprises in QoE always cost money.

This is one example of the dozens of procedure ratio benchmarks that algorithmic auditing tools evaluate. Crown-to-root-canal ratios, scaling-to-prophy ratios, periapical radiograph frequency, and procedure-specific coding patterns are all subject to the same type of analysis. PDA's compliance audit evaluates all of them — using the same institutional databases that a buyer's QoE team will use.

Scalable Hiring & Associate Structures

PDA reviews associate compensation structures for anomalies that create tax, labor classification, or QoE exposure.

1099 vs. W-2 classification

Associates classified as independent contractors (1099) who function as employees (set schedule, practice-provided equipment, practice-directed patient flow) create misclassification risk. The IRS and state labor boards apply multi-factor tests, and misclassification carries retroactive tax liability, penalties, and interest. In a transaction, this liability transfers to the buyer unless it's resolved pre-closing — and buyers will require indemnification or escrow.

Percentage-of-production without overhead allocation

Associates compensated on a straight percentage of production without allocated overhead (lab fees, assistant wages, supplies) inflate the apparent production value of the associate while obscuring their true cost to the practice. QoE teams will normalize associate compensation to include full overhead allocation, which often reveals that the associate is more expensive than the percentage suggests.

Non-compete and retention agreements

Associates without non-compete agreements, equity participation, or retention bonuses represent flight risk. If an associate generates 30-40% of the practice's production and has no contractual obligation to remain post-closing, the buyer will discount that production to zero in the go-forward model. This is one of the most overlooked valuation killers: a practice where significant production is generated by an associate with no financial or legal tether to the exit event. Buyers discount untransferable production — if the associate leaves, the revenue leaves with them.

System Consistency

Practices running multiple practice management systems, fragmented reporting tools, or inconsistent data architectures across locations create integration risk that buyers discount for.

The institutional standard is one system for all — production, scheduling, billing, analytics — with consistent data definitions and reporting methodology across every location. When a buyer's analyst requests production data and receives three different reports from three different systems with different coding conventions, the integration cost gets added to the deal model and deducted from the offer.

Multi-system environments also create data integrity risk: if production is tracked in one system, billing in another, and patient records in a third, the reconciliation between systems may not be clean. Discrepancies between systems raise questions about revenue accuracy that the seller must resolve during due diligence — at the worst possible time.

The Flight Risk Axiom

If your top-producing associate isn't financially or legally tethered to your exit event, you don't have Enterprise Value — you have flight risk. Buyers discount untransferable production to zero.

This is one of the most overlooked valuation killers in dental transactions. A practice where 30-40% of production is generated by an associate with no non-compete, no equity participation, and no retention agreement presents a straightforward risk calculation for the buyer: the moment the sale closes, that associate can walk. If they walk, they take their patient relationships and their production with them. The buyer's model must assume this possibility — and the discount is severe.

The remediation: retention agreements with meaningful financial incentives tied to the transaction, non-compete agreements that survive closing, or equity participation structures that align the associate's interests with the buyer's investment. These structures need to be in place 12-18 months before the transaction to be credible — last-minute retention agreements signal desperation rather than planning.